Program
Lutetium-177
Also written as “[177Lu]Lu-NeoB”, “[177Lu]Lu-PSMA-617” and “Lutetium[177Lu] Oxodotreotide Injection”.
In Novartis’s pipeline, Radioligand therapy target HER2
. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Neuroendocrine Tumors · Glioblastoma · Carcinoma, Non-Small-Cell Lung, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 107 open or running | phase 2since Dec 16, 2020 | Dec 16, 2020 | Dec 30, 2026phase 1 · NCT05870579 |
| Sinotau Pharmaceutical Groupits history only | 32 open or running | phase 3since Jul 5, 2022 | Jul 5, 2022 | Jun 1, 2027phase 3 · NCT06398444 |
| Bracco | 21 open or running | phase 2since May 20, 2022 | May 20, 2022 | none ahead |
| Sichuan Biokin Pharmaceuticalits history only | 22 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Dec 2027phase 1 · NCT07232407 |
| Affibodyits history only | 11 open or running | phase 1since Jun 23, 2025 | Jun 23, 2025 | Jun 1, 2027phase 1 · NCT07081555 |
| Alpha-9 Oncology USAits history only | 11 open or running | phase 1since Jun 9, 2026 | Jun 9, 2026 | Dec 2028phase 1 · NCT07661641 |
| Cellbionits history only | 11 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Apr 2029phase 1 · NCT07244393 |
| FutureChemits history only | 11 open or running | phase 2since Jun 10, 2022 | Jun 10, 2022 | none ahead |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since May 22, 2023 | May 22, 2023 | Dec 2026phase 3 · NCT05884255 |
| Philogenits history only | 11 open or running | phase 1since Oct 10, 2024 | Oct 10, 2024 | May 31, 2028phase 1 · NCT06640413 |
| Spago Nanomedical ABits history only | 11 open or running | phase 2since Dec 6, 2023 | Dec 6, 2023 | Dec 1, 2027phase 2 · NCT06184035 |
Also a collaborator on its studies: Merck, PSI CRO, Baili-Bio (Chengdu) Pharmaceutical and Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bracco only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2022First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT05413850 · 82 planned · United States, Belgium, Germany and more
- Jun 17, 2024Early phase 1 study in Prostatic NeoplasmsNCT06516510 · 17 enrolled · United States, Netherlands, Spain
TargetBeta
“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Gallium-68 | Philogen | phase 3 | 17 |
Studies
All 2 Bracco leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06516510Prostatic Neoplasms · United States, Netherlands, Spain | Early 1 | Terminated | Aug 15, 2025 | 17 |
| NCT05413850Prostatic Neoplasms · United States, Belgium, Germany and more | 2 | Recruiting | Aug 27, 2026 | 82 |
How it is read
Names in the registry
- “[177Lu]Lu-NeoB”, 4 entries
- “[177Lu]Lu-PSMA-617”, 3 entries
- “Lutetium[177Lu] Oxodotreotide Injection”, 2 entries
- “Lutetium [177Lu] BL-ARC001”, 2 entries
- “[177Lu]Lu-ABY-271”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 9 studies
- Breast Neoplasms, 5 studies
- Neuroendocrine Tumors, 1 study
- Glioblastoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.